Michael Scherz overview
Michael Scherz PhD is a Swiss citizen, raised in the USA and southern Germany. He completed his PhD in 1989 in synthetic-medicinal chemistry at the University of Oregon, in Eugene, OR, USA under the guidance of Prof. John Keana, and post-doctoral work in the central nervous system drug discovery group at F. Hoffman-La Roche in Basel, Switzerland, under the guidance of Drs. Ulrich Widmer and René Imhof. In 1992 he joined Procter & Gamble Pharmaceuticals in Cincinnati, OH, USA as synthetic-medicinal chemist. There he took on roles of increasing responsibility in the field of cardiac drug discovery, working on novel Class III anti-antiarrhythmic agents. In 2000 he joined Actelion Pharmaceuticals in Allschwil, Switzerland as head of Actelion’s then-planned US-based drug discovery center. Those plans were scuttled in 2003, and he moved into pre-clinical and clinical research and development at Actelion, ultimately as Vice President, Life Cycle Management, where he was responsible for the global development team efforts for, inter alia, palosuran, almorexant, and ponesimod. In late 2012 he left Actelion, began negotiations with Neurotune AG, and founded Metys Pharmaceuticals in April 2013 to re-start the clinical development of dimiracetam. He has co-authored 17 peer-reviewed publications, and is co-inventor on 18 issued patents. Mr. Scherz is a private pilot and avid hiker.